← Dentsply Sirona overview

Dentsply Sirona vs Neogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Dentsply Sirona Inc (XRAY)

Q3 2026
▲2▼1

Dentsply Sirona: weak sales, but profit recovery and dealer expansion

  • Sales still shrinking across all dental segments Second-quarter revenue fell 4.1% to $898 million, with weakness in all three dental segments, lower volumes in the Americas and Europe, soft demand for big-ticket equipment, and distributors cutting inventory. Falling sales pressure the stock even though profit beat expectations.

    The core reason XRAY is under pressure is that revenue is still declining, which matters more to long-term investors than a one-quarter profit beat.

  • Profit recovery and cash generation, guidance kept The company returned to net income with better margins and stronger cash flow, and kept its 2026 sales target of $3.5–$3.6 billion and adjusted earnings of $1.40–$1.50 per share. It also resumed buying back shares, a sign management sees value.

    Profit recovery and reaffirmed guidance are the main positive force supporting the stock despite weak sales.

  • Turnaround is uneven and back-loaded Management calls this a turnaround, but benefits from new sales hires and dealer additions mostly arrive in the fourth quarter and next year. Analysts questioned the timing of profit improvement, and cautious forecasts assume roughly flat revenue with only a small earnings recovery.

    This explains why the stock stays volatile: promised improvement keeps getting pushed into the future, so investors must wait.

  • Dealer network keeps expanding into technology Dentsply expanded distribution deals with Medline Sinclair in Canada and Midwest Dental in the US, bringing its digital dentistry equipment to more customers. These are the sixth and seventh North American dealer enhancements of 2026, widening reach for higher-priced technology products.

    Expanding distribution is the clearest new growth driver, aimed at reversing the equipment-demand weakness.

September 2026
▲2▼1

Dentsply Sirona: weak sales, but profit recovery and dealer expansion

  • Sales still shrinking across all dental segments Second-quarter revenue fell 4.1% to $898 million, with weakness in all three dental segments, lower volumes in the Americas and Europe, soft demand for big-ticket equipment, and distributors cutting inventory. Falling sales pressure the stock even though profit beat expectations.

    The core reason XRAY is under pressure is that revenue is still declining, which matters more to long-term investors than a one-quarter profit beat.

  • Profit recovery and cash generation, guidance kept The company returned to net income with better margins and stronger cash flow, and kept its 2026 sales target of $3.5–$3.6 billion and adjusted earnings of $1.40–$1.50 per share. It also resumed buying back shares, a sign management sees value.

    Profit recovery and reaffirmed guidance are the main positive force supporting the stock despite weak sales.

  • Turnaround is uneven and back-loaded Management calls this a turnaround, but benefits from new sales hires and dealer additions mostly arrive in the fourth quarter and next year. Analysts questioned the timing of profit improvement, and cautious forecasts assume roughly flat revenue with only a small earnings recovery.

    This explains why the stock stays volatile: promised improvement keeps getting pushed into the future, so investors must wait.

  • Dealer network keeps expanding into technology Dentsply expanded distribution deals with Medline Sinclair in Canada and Midwest Dental in the US, bringing its digital dentistry equipment to more customers. These are the sixth and seventh North American dealer enhancements of 2026, widening reach for higher-priced technology products.

    Expanding distribution is the clearest new growth driver, aimed at reversing the equipment-demand weakness.

Latest
▲2▼1

Dentsply Sirona: weak sales, but profit recovery and dealer expansion

  • Sales still shrinking across all dental segments Second-quarter revenue fell 4.1% to $898 million, with weakness in all three dental segments, lower volumes in the Americas and Europe, soft demand for big-ticket equipment, and distributors cutting inventory. Falling sales pressure the stock even though profit beat expectations.

    The core reason XRAY is under pressure is that revenue is still declining, which matters more to long-term investors than a one-quarter profit beat.

  • Profit recovery and cash generation, guidance kept The company returned to net income with better margins and stronger cash flow, and kept its 2026 sales target of $3.5–$3.6 billion and adjusted earnings of $1.40–$1.50 per share. It also resumed buying back shares, a sign management sees value.

    Profit recovery and reaffirmed guidance are the main positive force supporting the stock despite weak sales.

  • Turnaround is uneven and back-loaded Management calls this a turnaround, but benefits from new sales hires and dealer additions mostly arrive in the fourth quarter and next year. Analysts questioned the timing of profit improvement, and cautious forecasts assume roughly flat revenue with only a small earnings recovery.

    This explains why the stock stays volatile: promised improvement keeps getting pushed into the future, so investors must wait.

  • Dealer network keeps expanding into technology Dentsply expanded distribution deals with Medline Sinclair in Canada and Midwest Dental in the US, bringing its digital dentistry equipment to more customers. These are the sixth and seventh North American dealer enhancements of 2026, widening reach for higher-priced technology products.

    Expanding distribution is the clearest new growth driver, aimed at reversing the equipment-demand weakness.

Neogen Corporation (NEOG)

Q3 2026
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 2026
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.